Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses
Modeyso Included in National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma
Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355
Turnium and Syntheia AI Commence Commercial Rollout of AI-Powered Communications Platform Across Partner Network
Surface Metals Inc. Engages Barwicki Investor Relations to Lead Strategic Investor Relations and Shareholder Communication Program
Spartan Metals Provides Encouraging Drill Assay Results for Tungstonia Tailings at its Eagle Project, Nevada
Homerun Resources Inc. 100% Owned Subsidiary Homerun Energy SRL Recognized as Key Innovator by European Commission's Innovation Radar
